GILD · Gilead Sciences Inc.
AI read · Good for GILD
The AI's read
These results give Gilead a promising possible new treatment for ulcerative colitis. More patients improved or reached remission than on placebo, and side-effect rates were similar. The trial is still in Phase 2, and longer-term results are pending. The range of 12-week gains supports Gilead's drug pipeline, but the treatment has not yet shown how well it works over time.